Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

Presentation

CAR-T Therapy for Autoimmune Diseases: Applications, Outcomes, and Challenges

Description

The talk reviewed how CAR-T therapy may transform treatment of autoimmune diseases by targeting shared immune dysregulation seen in conditions such as lupus, dermatomyositis, systemic sclerosis, and other connective tissue diseases. The speaker explained the biology of autoimmunity, including loss of tolerance, B- and T-cell autoreactivity, interferon and myeloid amplification loops, autoantibody production, and tissue damage, and contrasted this with the broader immune “reset” that CAR-T may provide compared with conventional immunosuppressants or rituximab. The presentation described CAR-T design and delivery, typically autologous CD19 or BCMA-directed cells after leukapheresis and lymphodepletion, with the goal of drug-free remission. Early clinical data showed dramatic improvements in disease activity, steroid withdrawal, normalization of serologies, reduced CK in myositis, and improved skin, lung, and functional outcomes in systemic sclerosis and dermatomyositis, though long-term durability remains uncertain. Toxicities discussed included usually mild cytokine release syndrome, rare neurotoxicity, B-cell aplasia, cytopenias, infection risk, hypogammaglobulinemia, and common skin rashes or other drug eruptions requiring supportive care and steroids when needed. The field is rapidly expanding, with ongoing trials in additional diseases and emerging approaches such as allogeneic, dual-target, and disease-specific CAR-T constructs.

View more

Conclusions

Autoimmune connective tissue diseases appear to share a common biology of B-cell, T-cell, and interferon-driven immune dysregulation, making them plausible targets for CAR-T therapy.
CD19-directed CAR-T can produce deep, rapid, and sometimes drug-free remissions in highly refractory autoimmune diseases, especially lupus, myositis, dermatomyositis, and systemic sclerosis.
The early clinical signal suggests that CAR-T may function more like an immune reset than conventional immunosuppression, with transient B-cell aplasia followed by repopulation and clinical improvement.
Reported toxicities in autoimmune CAR-T studies are generally manageable, with mostly mild CRS, uncommon ICANS, and a need for infection, cytopenia, and IgG monitoring.
Skin findings after CAR-T are common but usually mild and nonspecific, so dermatologic surveillance and supportive treatment are important parts of care.
Current evidence is promising but still limited by small cohorts, selected patients, and short follow-up, so durability of response beyond B-cell recovery remains uncertain.
Systemic sclerosis and inflammatory myopathy data suggest CAR-T may not only improve skin and muscle disease but may also stabilize or improve lung involvement in some patients.
The CAR-T pipeline in autoimmunity is rapidly expanding beyond CD19 alone, and future trials may extend into BAFF-targeted, allogeneic, and disease-specific approaches as well as additional autoimmune diseases.

Kong Y. et al., FIMMU, 2025.
Baker DJ et al., Nature, 2023.
Mackensen et al.
Muller et al.
Auff et al.
Kreuter et al.